Exelixis (EXEL) Total Non-Current Liabilities (2010 - 2026)
Exelixis' (EXEL) quarterly Total Non-Current Liabilities came in at $540.5 million in Q2 2026, down 7.8% year-on-year from $586.2 million in Q2 2025, and down 6.6% quarter-over-quarter from $578.7 million in Q1 2026.
Exelixis (EXEL) Total Non-Current Liabilities (2010 - 2026) Analysis & Trends
Exelixis' Total Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $540.5 million for Q2 2026.
- On a quarterly basis, Total Non-Current Liabilities fell 7.8% year-over-year to $540.5 million in Q2 2026; TTM through Apr 2026 was $540.5 million, a 7.8% decrease from a year earlier, with the FY2026 full-year figure at $578.7 million, down 2.68% from the prior year.
- Total Non-Current Liabilities eased to $540.5 million in Q2 2026 per EXEL's latest filing, from $578.7 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $594.6 million in Q1 2025 and bottomed at $347.8 million in Q2 2022.
- The 5-year median for Total Non-Current Liabilities is $543.7 million (2024), against an average of $534.7 million.
- Across the five-year window, Total Non-Current Liabilities soared 49.78% in 2023 and decreased 7.8% in 2026, its largest moves.
- Year by year, Total Non-Current Liabilities stood at $514.5 million in 2022, then rose by 13.54% to $584.2 million in 2023, then rose by 0.78% to $588.8 million in 2024, then retreated by 6.55% to $550.2 million in 2025, then retreated by 1.77% to $540.5 million in 2026.
- Per Business Quant, the three latest EXEL Total Non-Current Liabilities figures stand at $540.5 million (Q2 2026), $578.7 million (Q1 2026), and $550.2 million (Q4 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Exelixis | 14.38 Bn | 13.60 Bn | 590.86 Mn | 540.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 540.52 Mn |
| Jan 2, 2026 | 578.68 Mn |
| Oct 3, 2025 | 550.24 Mn |
| Jul 4, 2025 | 515.95 Mn |
| Apr 4, 2025 | 586.23 Mn |
| Jan 3, 2025 | 594.59 Mn |
| Sep 27, 2024 | 588.79 Mn |
| Jun 28, 2024 | 543.72 Mn |
| Mar 29, 2024 | 574.48 Mn |
| Dec 29, 2023 | 584.22 Mn |
| Sep 29, 2023 | 567.67 Mn |
| Jun 30, 2023 | 541.04 Mn |
| Mar 31, 2023 | 520.84 Mn |
| Dec 30, 2022 | 514.53 Mn |
| Sep 30, 2022 | 468.06 Mn |
| Jul 1, 2022 | 472.75 Mn |
| Apr 1, 2022 | 347.75 Mn |
| Dec 31, 2021 | 397.60 Mn |
| Oct 1, 2021 | 331.20 Mn |
| Jul 2, 2021 | 317.13 Mn |